Payment overview · 2025
General Payments
$3,036.90
153 reported records · 21 companies
Healthcare provider profile · identity verified
Bryan Johannes Vekovius, M.D.
Allopathic & Osteopathic Physicians|Ophthalmology|Neuro-ophthalmology · SHREVEPORT, LA · NPI 1285674820
Verified facts
What the public records show
CMS Open Payments records show Bryan Johannes Vekovius, M.D. received $3,036.90 in general payments during 2025 across 153 reported records.
Amgen Inc. accounted for 12.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 30 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Miebo, Qulipta, Tepezza, Tyrvaya, Ultomiris, Vevye, Xiidra.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BOTOX as an associated drug or biological on 140321 records involving 30103 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Botox by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Qulipta by this doctor in 2024.
Alcon Vision LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported EYSUVIS as an associated drug or biological on 4201 records involving 2750 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Eysuvis by this doctor in 2024.
Alexion Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ULTOMIRIS as an associated drug or biological on 24281 records involving 10608 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Ultomiris by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TEPEZZA as an associated drug or biological on 32661 records involving 9684 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Tepezza by this doctor in 2024.
Bausch & Lomb Americas Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOTEMAX SM as an associated drug or biological on 92 records involving 67 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Lotemax Sm by this doctor in 2024.
Bausch & Lomb Americas Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MIEBO as an associated drug or biological on 34133 records involving 12967 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Miebo by this doctor in 2024.
Bausch & Lomb Americas Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIIDRA as an associated drug or biological on 28163 records involving 11019 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Xiidra by this doctor in 2024.
Harrow Eye, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VEVYE as an associated drug or biological on 14430 records involving 6429 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Vevye by this doctor in 2024.
Oyster Point Pharma, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TYRVAYA as an associated drug or biological on 8925 records involving 5041 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Tyrvaya by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $386.24 | 12.7% | 23 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $261.65 | 8.6% | 11 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $259.59 | 8.6% | 12 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $258.12 | 8.5% | 22 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $247.62 | 8.2% | 12 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $217.30 | 7.2% | 13 | 2025 |
| BIOTISSUE HOLDINGS INC. | Unresolved — no canonical attribution shown | $203.60 | 6.7% | 4 | 2025 |
| Bausch & Lomb Americas Inc. | Unresolved — no canonical attribution shown | $176.40 | 5.8% | 12 | 2025 |
| Harrow Eye, LLC | Unresolved — no canonical attribution shown | $162.91 | 5.4% | 7 | 2025 |
| SpringWorks Therapeutics, Inc. | Unresolved — no canonical attribution shown | $135.51 | 4.5% | 5 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $105.29 | 3.5% | 4 | 2025 |
| Alcon Vision LLC | Unresolved — no canonical attribution shown | $95.05 | 3.1% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $87.59 | 2.9% | 4 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $80.99 | 2.7% | 3 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $80.25 | 2.6% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $76.46 | 2.5% | 4 | 2025 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | Unresolved — no canonical attribution shown | $67.00 | 2.2% | 3 | 2025 |
| Oyster Point Pharma, Inc. | Unresolved — no canonical attribution shown | $46.82 | 1.5% | 2 | 2025 |
| MERZ NORTH AMERICA, INC. | Unresolved — no canonical attribution shown | $37.15 | 1.2% | 1 | 2025 |
| Tarsus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $35.40 | 1.2% | 1 | 2025 |
| Thea Pharma Inc. | Unresolved — no canonical attribution shown | $15.96 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,036.90 | 153 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $295.92 | 18 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $261.65 | 11 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $247.62 | 12 | 2025 |
Source payment records
|
|||||
| Zilbrysq Normalized: zilbrysq |
Drug | UCB, Inc. | $242.43 | 11 | 2025 |
Source payment records
|
|||||
| VYVGART Normalized: vyvgart |
Drug | ARGENX US, INC. | $217.30 | 13 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $217.30 | 13 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $197.60 | 19 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $179.82 | 18 | 2025 |
Source payment records
|
|||||
| VEVYE Normalized: vevye |
Drug | Harrow Eye, LLC | $162.91 | 7 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | MERZ NORTH AMERICA, INC., Merz Pharmaceuticals, LLC | $142.44 | 5 | 2025 |
Source payment records
|
|||||
| GOMEKLI Normalized: gomekli |
Drug | SpringWorks Therapeutics, Inc. | $135.51 | 5 | 2025 |
Source payment records
|
|||||
| MIEBO Normalized: miebo |
Drug | Bausch & Lomb Americas Inc. | $92.31 | 6 | 2025 |
Source payment records
|
|||||
| XIIDRA Normalized: xiidra |
Drug | Bausch & Lomb Americas Inc. | $92.31 | 6 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $90.32 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $87.59 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $87.59 | 4 | 2025 |
Source payment records
|
|||||
| VYZULTA Normalized: vyzulta |
Drug | Bausch & Lomb Americas Inc. | $84.09 | 6 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $80.99 | 3 | 2025 |
Source payment records
|
|||||
| Rocklatan Normalized: rocklatan |
Drug | Alcon Vision LLC | $76.46 | 4 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $76.46 | 4 | 2025 |
Source payment records
|
|||||
| Cequa Normalized: cequa |
Drug | SUN PHARMACEUTICAL INDUSTRIES INC. | $67.00 | 3 | 2025 |
Source payment records
|
|||||
| DURYSTA Normalized: durysta |
Drug | ABBVIE INC. | $60.52 | 3 | 2025 |
Source payment records
|
|||||
| RYZUMVI Normalized: ryzumvi |
Drug | Oyster Point Pharma, Inc. | $46.82 | 2 | 2025 |
Source payment records
|
|||||
| TYRVAYA Normalized: tyrvaya |
Drug | Oyster Point Pharma, Inc. | $46.82 | 2 | 2025 |
Source payment records
|
|||||
| XDEMVY Normalized: xdemvy |
Drug | Tarsus Pharmaceuticals, Inc. | $35.40 | 1 | 2025 |
Source payment records
|
|||||
| AMPYRA Normalized: ampyra |
Drug | Merz Pharmaceuticals, LLC | $20.24 | 1 | 2025 |
Source payment records
|
|||||
| INBRIJA Normalized: inbrija |
Drug | Merz Pharmaceuticals, LLC | $20.24 | 1 | 2025 |
Source payment records
|
|||||
| TRYPTYR Normalized: tryptyr |
Drug | Alcon Vision LLC | $18.59 | 1 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $17.16 | 1 | 2025 |
Source payment records
|
|||||
| IYUZEH Normalized: iyuzeh |
Drug | Thea Pharma Inc. | $15.96 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MIEBO miebo |
2025 | Miebo | 2024 | 32 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TEPEZZA tepezza |
2025 | Tepezza | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TYRVAYA tyrvaya |
2025 | Tyrvaya | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ULTOMIRIS ultomiris |
2025 | Ultomiris | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VEVYE vevye |
2025 | Vevye | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIIDRA xiidra |
2025 | Xiidra | 2024 | 57 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | BOTOX open payments reported associated product |
CMS Open Payments — General Payments 140321 supporting records · 30103 recipient NPIs · example record 1201352642 |
Botox · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Alcon Vision LLC Exact reporting entity; no affiliate inference |
2025 | EYSUVIS open payments reported associated product |
CMS Open Payments — General Payments 4201 supporting records · 2750 recipient NPIs · example record 1207357018 |
Eysuvis · 2024 Exact normalized brand match · 1 Part D row |
32 | 28 |
| Alexion Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | ULTOMIRIS open payments reported associated product |
CMS Open Payments — General Payments 24281 supporting records · 10608 recipient NPIs · example record 1202912926 |
Ultomiris · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | TEPEZZA open payments reported associated product |
CMS Open Payments — General Payments 32661 supporting records · 9684 recipient NPIs · example record 1226871638 |
Tepezza · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Bausch & Lomb Americas Inc. Exact reporting entity; no affiliate inference |
2025 | LOTEMAX SM open payments reported associated product |
CMS Open Payments — General Payments 92 supporting records · 67 recipient NPIs · example record 1254732081 |
Lotemax Sm · 2024 Exact normalized brand match · 1 Part D row |
63 | 60 |
| Bausch & Lomb Americas Inc. Exact reporting entity; no affiliate inference |
2025 | MIEBO open payments reported associated product |
CMS Open Payments — General Payments 34133 supporting records · 12967 recipient NPIs · example record 1254730224 |
Miebo · 2024 Exact normalized brand match · 1 Part D row |
32 | 18 |
| Bausch & Lomb Americas Inc. Exact reporting entity; no affiliate inference |
2025 | XIIDRA open payments reported associated product |
CMS Open Payments — General Payments 28163 supporting records · 11019 recipient NPIs · example record 1254730224 |
Xiidra · 2024 Exact normalized brand match · 1 Part D row |
57 | 29 |
| Harrow Eye, LLC Exact reporting entity; no affiliate inference |
2025 | VEVYE open payments reported associated product |
CMS Open Payments — General Payments 14430 supporting records · 6429 recipient NPIs · example record 1236209940 |
Vevye · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Oyster Point Pharma, Inc. Exact reporting entity; no affiliate inference |
2025 | TYRVAYA open payments reported associated product |
CMS Open Payments — General Payments 8925 supporting records · 5041 recipient NPIs · example record 1238388111 |
Tyrvaya · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Erythromycin | Erythromycin Base | 1242 | 659 |
| Latanoprost | Latanoprost | 757 | 182 |
| Ondansetron Hcl | Ondansetron Hcl | 377 | 331 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 313 | 272 |
| Restasis | Cyclosporine | 183 | 86 |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 143 | 30 |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 130 | 40 |
| Acetazolamide Er | Acetazolamide | 101 | 20 |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 90 | 24 |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 88 | 75 |
| Doxycycline Hyclate | Doxycycline Hyclate | 86 | 46 |
| Prednisone | Prednisone | 71 | 29 |
| Lotemax Sm | Loteprednol Etabonate | 63 | 60 |
| Xiidra | Lifitegrast | 57 | 29 |
| Ofloxacin | Ofloxacin | 55 | 44 |
| Brimonidine Tartrate | Brimonidine Tartrate | 54 | 20 |
| Cyclosporine | Cyclosporine | 52 | 35 |
| Gabapentin | Gabapentin | 49 | 18 |
| Loteprednol Etabonate | Loteprednol Etabonate | 40 | 32 |
| Tramadol Hcl | Tramadol Hcl | 40 | 37 |
| Topiramate | Topiramate | 38 | 11 |
| Eysuvis | Loteprednol Etabonate | 32 | 28 |
| Miebo | Perfluorohexyloctane/Pf | 32 | 18 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 30 | 28 |
| Potassium Chloride | Potassium Chloride | 28 | suppressed |
| Methocarbamol | Methocarbamol | 27 | 12 |
| Ultomiris | Ravulizumab-Cwvz | 27 | suppressed |
| Vevye | Cyclosporine | 26 | suppressed |
| Timolol Maleate | Timolol Maleate | 24 | suppressed |
| Zylet | Tobramycin/Lotepred Etab | 21 | 17 |
| Qulipta | Atogepant | 18 | suppressed |
| Tepezza | Teprotumumab-Trbw | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Lorazepam | Lorazepam | 16 | 14 |
| Sodium Chloride | 0.9 % Sodium Chloride | 16 | suppressed |
| Dorzolamide-Timolol | Dorzolamide/Timolol/Pf | 15 | suppressed |
| Fluorometholone | Fluorometholone | 15 | 12 |
| Ondansetron Odt | Ondansetron | 14 | 14 |
| Tyrvaya | Varenicline Tartrate | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Botox | Onabotulinumtoxina | 12 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Moxifloxacin | Moxifloxacin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,036.90 · 153 records | Amgen Inc. | ACTHAR, AMPYRA, Cequa, DURYSTA, GOMEKLI, INBRIJA, IYUZEH, MIEBO, NURTEC ODT, PURIFIED CORTROPHIN GEL, QULIPTA, RYZUMVI, Rocklatan, Rystiggo, TEPEZZA, TRYPTYR, TYRVAYA, UBRELVY, ULTOMIRIS, UPLIZNA, VEVYE, VYEPTI, VYVGART, VYVGART HYTRULO, VYZULTA, XDEMVY, XIIDRA, Xeomin, ZAVZPRET, Zilbrysq | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Miebo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error